Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus

Hormones

Volumn 14, Issue 1, 2015, Pages 118-125

  Zografou, Ioanna ^a   Sampanis, Christos ^a   Gkaliagkousi, Eugenia ^a   Iliadis, Fotios ^a   Papageorgiou, Athanasios ^a   Doukelis, Panagiotis ^b   Vogiatzis, Konstantinos ^a   Douma, Stella ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Arterial stiffness; Dipeptidyl peptidase 4 inhibitor; High sensitivity C reactive protein; Pulse wave velocity; Vildagliptin

Indexed keywords

ALBUMIN; C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; TRIACYLGLYCEROL; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; NITRILE; PYRROLIDINE DERIVATIVE;

ADULT; ALBUMIN BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CAROTID ARTERY; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DRUG EFFECT; FEMALE; FEMORAL ARTERY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; PULSE WAVE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADAMANTANE; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PULSE WAVE ANALYSIS; PYRROLIDINES; VASCULAR STIFFNESS;

EID: 84927633440     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. King H, Aubert RE, Herman WH, 1998 Global burden of diabetes, 1995–2005. Prevalence, numerical estimates, projections. Diabetes Care 21: 1414-1431.
2. Brand FN, Abbot RD, Kannel WB, 1989 Diabetes, intermittent claudication and risk of cardiovascular events. The Framingham study. Diabetes 38: 504-509.
3. UK Prospective Diabetes Study (UKPDS) Group, 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865.
4. Holman R, Retnakaran R, Farmer A, Stevens R, 2006 PROactive study. Lancet 367: 25-26.
5. Kieffer TJ, Habener JF, 1999 The glucagon-like pep-tides. Endocr Rev 20: 876-913.
6. Kieffer TJ, McIntosh CH, Pederson RA, 1995 Degrada-tion of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596.
7. Mu J, Woods J, Zhou YP, 2006 Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic b-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55: 1695-1704.
8. Ahrén B, 2008 Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 13: 593-607.
9. Nyström T, Gutniak MK, Zhang Q, et al, 2004 Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215.
10. Ban K, Noyan-Ashraf M, Hoefer J, Bolz SS, Drucker DJ, Husain M, 2008 Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are medi-ated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340-2350.
11. Mari A, Sallas WM, He YL, et al, 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90: 4888-4894.
12. Derosa G, Ragonesi PD, Carbone A, et al, 2012 Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother 13: 2581-2591.
13. Shah Z, Kampfrath T, Deiuliis JA, et al, 2011 Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124: 2338-2349.
14. Van Poppel PC, Netea MG, Smits P, Tack CJ, 2011 Vildagliptin improves endothelium-dependent vasodila-tation in type 2 diabetes. Diabetes Care 34: 2072-2077.
15. Boutouyrie P, Tropeano AI, Asmar R, et al, 2002 Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 39: 10-15.
16. Asmar R, Rudnichi A, Blacher J, London GM, Safar ME, 2001 Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive popula-tions. Am J Hypertens 14: 91-97.
17. Strandberg TE, Salomaa VV, Vanhanen HT, Pitkala K, Miettinen TA, 2002 Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predic-tors of mortality during a follow-up of up to 32 years. J Hypertens 20: 399-404.
18. Roman MJ, Deveraux RB, Schwartz JE, et al, 2005 Arterial stiffness in chronic inflammatory diseases. Hypertension 46: 194-199.
19. Vlachopoulos C, Dima I, Aznaouridis K, et al, 2005 Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 112: 2193-2200.
20. Maki-Pataja KM, Booth AD, Hall FC, et al, 2007 Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50: 852-858.
21. The Reference Values for Arterial Stiffness Collabo-ration, 2010 Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 31: 2338-2350.
22. Mackenzie IS, Wilkinson IB, Cockroft J, 2002 Assessment of arterial stiffness in clinical practice. QJM 95: 67-74.
23. Friedewald WT, Levy RI, Fredrickson DS, 1972 Esti-mation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, 1985 Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
25. Pickup JC, Crook MA, 1998 Is type II diabetes mellitus a disease of the innate immune system ? Diabetologia 41: 1241-1248.
26. Tedesco MA, Natale F, Di Salvo G, Caputo S, Capasso M, Calabro R, 2004 Effects of coexisting hypertension and type II diabetes mellitus on arterial stiffness. J Hum Hypertens 18: 469-473.
27. Lee JM, Shirodaria C, Jackson CE, et al, 2007 Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 4: 44-48.
28. Van Der Meer RW, Diamant M, Westenberg JJ, et al, 2007 Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson 9: 645-651.
29. Theilade S, Lajer M, Persson F, Joergensen C, Rossing P, 2013 Arterial stiffness is associated with cardiovascular, renal, retinal and autonomic disease in type 1 diabetes. Diabetes Care 36: 715-721.
30. Keating GM, 2010 Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 70: 2089-2112.
31. Yin M, Silljé HH, Meissner M, Van Gilst WH, De Boer RA, 2011 Early and late effects of the DPP-4 inhibitor vildagliptin in rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 1186/1475-2840-10-85.
32. Shah Z, Pineda C, Kampfrath T, et al, 2011 Acute DPP- 4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 55: 2-9.
33. Matsui T, Nishino Y, Takeuchi M, Yamagishi S, 2011 Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 63: 383-388.
34. Derosa G, Maffiloi P, 2012 Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabet Technol Ther 14: 350-364.
35. Derosa G, Maffioli P, Ferrari I, et al, 2010 Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 42: 663-669.
36. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockroft JR, Wilkinson IB, 2004 C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 24: 969-974.
37. Kim JS, Kang TS, Kim JB, et al, 2007 Significant as-sociation of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 192: 401-406.
38. Agarwal N, Rice SP, Bolusani H, et al, 2010 Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 95: 722-730.
39. Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H, 2005 Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 91: 589-594.
40. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ, 2007 Effects of vildagliptin on glucose control over 24 weekes in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30: 890-895.
41. Ahren B, Pacini G, Tura A, Folley JE, Schweizer A, 2007 Improved meal-related insulin processing con-tributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in type 2 diabetes. Horm Metab Res 39: 826-829.
42. Utzschneider KM, Tong J, Montgomery B, 2008 The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31: 108-113.
43. Vilsbøll T, 2007 Liraglutide: an once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 16: 231-237.